BRISBANE, Calif. and ST. LOUIS, Jan. 06, 2021 (GLOBE NEWSWIRE) — Arch Oncology, Inc., a clinical-stage immuno-oncology company focused on the discovery and development of anti-CD47 antibody therapies, today announced that Julie Hambleton, M.D., the Company’s Interim President and Chief Executive Officer, will present at the 39th Annual J.P. Morgan Healthcare Conference.
Event: 39th Annual J.P. Morgan Healthcare Conference
Date: January 14, 2021 12:10-12:35 pm ET
About Arch Oncology
Arch Oncology, Inc. is a privately-held, clinical-stage immuno-oncology company focused on the discovery and development of potential best-in-class antibody therapies for the treatment of patients with solid tumors and hematologic malignancies. The Company’s next-generation anti-CD47 antibodies are highly differentiated, with the potential to improve upon the safety and efficacy profile relative to other agents in this class. Arch Oncology’s lead product candidate AO-176 is in two Phase 1/2 clinical trials for the treatment of patients with select solid tumors and with multiple myeloma, both as monotherapy and in combination with standard therapies. In addition, the Company is advancing a pipeline of antibody programs for the treatment of cancer. For more information, please visit www.archoncology.com.
Contact: Amy Figueroa, CFA For Arch Oncology [email protected]